混合多模式融合与跨领域的知识转移,以预测认知衰退的进展轨迹
Minhui Yu1,2, Yunbi Liu3, Jinjian Wu4
1Department of Radiology and BRIC, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention
|March 4, 2024
概括
这项研究引入了一种混合融合框架,将MRI和PET扫描结合起来,用于预测阿尔茨海默病 (AD) 的认知衰退. 该方法有效地处理缺失的数据,并提高预测在早期AD阶段的准确性.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 磁共振成像 (MRI) 和正子发射断层扫描 (PET) 对于预测阿尔茨海默病 (AD) 的认知衰退至关重要.
- 由于模式差异和缺少数据,将MRI和PET数据合并是具有挑战性的.
- 现有的机器和深度学习方法已经探索了这些模式,取得了不同程度的成功.
研究的目的:
- 为联合MRI和PET表示学习开发混合多式融合 (HMF) 框架.
- 为了能够准确预测临床前和临床前AD的认知衰退进展.
- 在AD神经成像研究中解决缺失的模式和小样本大小的挑战.
主要方法:
- 开发了一个混合多模式融合 (HMF) 框架,包含三个模块:PET归算,多模式特征提取和特征融合.
- 实施了跨领域的知识转移策略,从大型ADNI数据集到较小的AD队列.
- 利用联合表示学习进行综合MRI和PET数据分析.
主要成果:
- 该HMF框架在预测AD相关认知衰退进展方面表现出卓越的表现.
- 成功处理缺失的PET数据,并将MRI和PET模式的信息合并.
- 在多个疾病阶段的评估中超越了几种最先进的方法.
结论:
- 拟议的HMF框架为在AD研究中利用多式联络神经成像数据提供了一种有效的方法.
- 跨领域的知识转移有利于改善小规模数据集的模型性能.
- 通过先进的融合技术,可以准确预测认知衰退轨迹.
相关概念视频
01:30Cognitive Development During Adulthood
105
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
105
01:26Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188